1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1528038841

DR. DALE J LANGE M.D.
Prescription History 1528038841
Psychiatry & Neurology - Neurology in New York, NY

NPI Status: Active since January 26, 2006

Contact Information

800A 5TH AVE STE 203
NEW YORK, NY
ZIP 10065
Phone: (332) 334-6637

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DALE J LANGE M.D., an active Neurology specialist practicing in New York, NY. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 106 documented patient claims. Among these therapy options, the most frequently utilized medication is Gamunex-C, which accounts for 33 claims alone.

Medication Index

C
G
P
No matching medications currently found on file.

Carbidopa-Levodopa

Generic Formulation: Carbidopa/LevodopaSpecialty: Neurology
Provider Metrics Summary
Total Claims 16
30-Day Fills 20.0
Days Supply 600
NY State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills101.2
Peer Average Days Supply2,874
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 74.2% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $226.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.13

State Avg Cost Per Claim

$42.15

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). Parkinson's disease is thought to be caused by too little of a naturally occurring substance (dopamine) in the brain. Levodopa changes into dopamine in the brain, helping to control movement. Carbidopa prevents the breakdown of levodopa in the bloodstream so more levodopa can enter the brain. Carbidopa can also reduce some of levodopa's side effects such as nausea and vomiting.

Gammagard S-D

Generic Formulation: Immun Glob G/Gly/Gluc/Iga 0-50Specialty: Neurology
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 455
NY State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.0
Peer Average Days Supply479
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $342,940.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$20,173.00

State Avg Cost Per Claim

$17,265.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to strengthen the body's natural defense system (immune system) to lower the risk of infection in persons with a weakened immune system. This medication is made from healthy human blood that has a high level of certain defensive substances (antibodies), which help fight infections. It is also used to increase the blood count (platelets) in persons with a certain blood disorder (idiopathic thrombocytopenia purpura-ITP). Platelets are needed to stop bleeding and form blood clots. Some immune globulin products may also be used to treat certain types of muscle weakness problem (multifocal motor neuropathy, dermatomyositis) or a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). Some products may also be used to prevent certain blood vessel disorders in people with Kawasaki syndrome.

Gamunex-C

Generic Formulation: Immune Globul G/Gly/Iga Avg 46Specialty: Neurology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 883
NY State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills34.5
Peer Average Days Supply895
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $437,238.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,249.65

State Avg Cost Per Claim

$11,000.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used in people with a certain type of weakened immune system (primary immune deficiency) to strengthen it and to lower the risk of infection. This medication is made from human blood that has a high level of antibodies which help fight infections. This product is also used to increase the number of certain blood cells (platelets) in people with a certain blood disorder (idiopathic thrombocytopenic purpura-ITP). Platelets are needed to stop bleeding and to form normal blood clots. In addition, this medication is used to treat a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). This disorder causes weakness and numbness/tingling/pain in the arms and legs. This medication helps to improve these symptoms and prevents relapse.

Prednisone

Generic Formulation: PrednisoneSpecialty: Neurology
Provider Metrics Summary
Total Claims 15
30-Day Fills 16.0
Days Supply 460
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,023
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $100.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.73

State Avg Cost Per Claim

$6.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Privigen

Generic Formulation: Immun Glob G(Igg)/Pro/Iga 0-50Specialty: Neurology
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 655
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.0
Peer Average Days Supply606
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $572,555.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$22,902.22

State Avg Cost Per Claim

$11,815.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to boost the body's natural defense system against infection in persons with a weakened immune system (primary immune deficiency). Immune globulin contains natural substances called antibodies (a type called IgG) that come from healthy human blood (plasma). These antibodies help protect your body against infections and help you to fight an infection if you get sick. Some immune globulin products may also be used to treat a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DALE J LANGE M.D. provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Neurology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.